论文部分内容阅读
以活血化瘀中药为主结合西医对症支持治疗慢乙肝１７５例，平均治疗６０．８６±１１．５３ｄ，结果总有效率８８．５７％，明显优于对照组的６８．８２％（Ｐ＜０．０５）。在降ＡＬＴ、提升血浆白蛋白、调节白／球蛋白比值方面，观察组亦明显优于对照组（Ｐ＜０．０１）。ＨＢｅＡｇ阴转率、抗－ＨＢｅ阳转率，两组比较亦有显著性差异（Ｐ＜０．０５）。提示观察组在抑制ＨＢＶ复制，促进抗－ＢＨｅ阳转方面优于对照组；从免疫功能测定来看，治疗后观察组的Ｅ－ＲＦＣ均值升高，ＩｇＧ均值降低，并有统计学意义，表明对患者紊乱的免疫功能有一定调节作用。平均治疗日数观察组亦较对照组明显缩短（Ｐ＜０．０１）。在用药期间亦未发现任何副作用。经２年随访观察，观察组中有１例发生肝硬变，对照组有７例发生肝硬变，其中２例死于肝功能衰竭，两组差异有显著意义（Ｐ＜０．０１）。
175 cases of chronic hepatitis B were treated mainly with traditional Chinese medicine and symptomatic supportive therapy of blood circulation and blood circulation, the average treatment was 60.86 ± 11.53 days, the total effective rate was 88.57%, which was significantly better than that of the control group (68.82%, P0.01) .05). The observation group was also significantly better than the control group (P <0.01) in lowering ALT, promoting plasma albumin, and adjusting white / globular ratio. HBeAg negative rate, anti-HBe positive rate, the two groups also had significant difference (P <0.05). Suggesting that the observation group is superior to the control group in inhibiting HBV replication and promoting anti-BHe positive conversion. From the point of view of immune function, the mean of E-RFC in the observation group increased and the IgG mean decreased after treatment, indicating that Immune function of patients with disorders have a regulatory role. The average number of treatment days in the observation group was also significantly shorter than the control group (P <0.01). During the medication did not find any side effects. After 2 years’ follow-up, one case of liver cirrhosis was observed in the observation group, and cirrhosis was found in 7 cases in the control group, of which 2 cases died of liver failure. There was significant difference between the two groups (P <0.01).